Chemokines as therapeutic targets in renal cell carcinoma

References

• Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon α in metastatic renal-cell carcinoma. N. Engl. J. Med.356, 115–124 (2007).
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med.356, 125–134 (2007).
   PubMed Web of Science ®Google Scholar
• Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon α-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind Phase III trial. Lancet370, 2103–2111 (2007).
   PubMed Web of Science ®Google Scholar
• Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon α, or both for advanced renal-cell carcinoma. N. Engl. J. Med.356, 2271–2281 (2007).
   PubMed Web of Science ®Google Scholar
• Rini BI, Halabi S, Rosenberg JE et al. CALGB 90206: a Phase III trial of bevacizumab plus interferon-α versus interferon-α monotherapy in metastatic renal cell carcinoma. 2008 Genitourniary Cancers Symp. (2008) (Abstract 350).
   Google Scholar
• Atkins MB, Ernstoff MS, Figlin RA et al. Innovations and challenges in renal cell carcinoma: summary statement from the Second Cambridge Conference. Clin. Cancer Res.13, S667–S670 (2007).
   Google Scholar
• Balkwill F. Cancer and the chemokine network. Nat. Rev. Cancer4, 540–550 (2004).
   PubMed Web of Science ®Google Scholar
• Spring H, Schuler T, Arnold B, Hammerling GJ, Ganss R. Chemokines direct endothelial progenitors into tumor neovessels. Proc. Natl Acad. Sci. USA102, 18111–18116 (2005).
   PubMed Web of Science ®Google Scholar
• Gupta SK, Lysko PG, Pillarisetti K, Ohlstein E, Stadel JM. Chemokine receptors in human endothelial cells. Functional expression of CXCR4 and its transcriptional regulation by inflammatory cytokines. J. Biol. Chem.273, 4282–4287 (1998).
   PubMed Web of Science ®Google Scholar
• Muller A, Homey B, Soto H et al. Involvement of chemokine receptors in breast cancer metastasis. Nature410, 50–56 (2001).
   PubMed Web of Science ®Google Scholar
• Scotton CJ, Wilson JL, Scott K et al. Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. Cancer Res.62, 5930–5938 (2002).
   PubMed Web of Science ®Google Scholar
• Coussens LM, Werb Z. Inflammation and cancer. Nature420, 860–867 (2002).
   PubMed Web of Science ®Google Scholar
• Locati M, Deuschle U, Massardi ML et al. Analysis of the gene expression profile activated by the CC chemokine ligand 5/RANTES and by lipopolysaccharide in human monocytes. J. Immunol.168, 3557–3562 (2002).
   PubMed Web of Science ®Google Scholar
• Roda JM, Parihar R, Magro C, Nuovo GJ, Tridandapani S, Carson WE III. Natural killer cells produce T cell-recruiting chemokines in response to antibody-coated tumor cells. Cancer Res.66, 517–526 (2006).
   PubMed Web of Science ®Google Scholar
• Bukowski RM, Rayman P, Molto L et al. Interferon-gamma and CXC chemokine induction by interleukin 12 in renal cell carcinoma. Clin. Cancer Res.5, 2780–2789 (1999).
   PubMed Web of Science ®Google Scholar
• Mestas J, Burdick MD, Reckamp K, Pantuck A, Figlin RA, Strieter RM. The role of CXCR2/CXCR2 ligand biological axis in renal cell carcinoma. J. Immunol.175, 5351–5357 (2005).
   PubMed Web of Science ®Google Scholar
• Guha S, Eibl G, Kisfalvi K et al. Broad-spectrum G protein-coupled receptor antagonist, [D-Arg1,D-Trp5,7,9,Leu11]SP: a dual inhibitor of growth and angiogenesis in pancreatic cancer. Cancer Res.65, 2738–2745 (2005).
   PubMed Web of Science ®Google Scholar
• Wang B, Hendricks DT, Wamunyokoli F, Parker MI. A growth-related oncogene/CXC chemokine receptor 2 autocrine loop contributes to cellular proliferation in esophageal cancer. Cancer Res.66, 3071–3077 (2006).
   PubMed Web of Science ®Google Scholar
• Donzella GA, Schols D, Lin SW et al. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat. Med.4, 72–77 (1998).
   PubMed Web of Science ®Google Scholar
• Martinez MA, Gutierrez A, Armand-Ugon M et al. Suppression of chemokine receptor expression by RNA interference allows for inhibition of HIV-1 replication. Aids16, 2385–2390 (2002).
   PubMed Web of Science ®Google Scholar
• Zhang WB, Navenot JM, Haribabu B et al. A point mutation that confers constitutive activity to CXCR4 reveals that T140 is an inverse agonist and that AMD3100 and ALX40–4C are weak partial agonists. J. Biol. Chem.277, 24515–24521 (2002).
   PubMed Web of Science ®Google Scholar
• Kakinuma T, Hwang ST. Chemokines, chemokine receptors, and cancer metastasis. J. Leukoc. Biol.79, 639–651 (2006).
   PubMed Web of Science ®Google Scholar
• Gnarra JR, Tory K, Weng Y et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat. Genet.7, 85–90 (1994).
   PubMed Web of Science ®Google Scholar
• Herman JG, Latif F, Weng Y et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc. Natl Acad. Sci. USA91, 9700–9704 (1994).
   PubMed Web of Science ®Google Scholar
• Strieter RM, Polverini PJ, Kunkel SL et al. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J. Biol. Chem.270, 27348–27357 (1995).
   PubMed Web of Science ®Google Scholar
• Wente MN, Keane MP, Burdick MD et al. Blockade of the chemokine receptor CXCR2 inhibits pancreatic cancer cell-induced angiogenesis. Cancer Lett.241, 221–227 (2006).
   PubMed Web of Science ®Google Scholar
• Strieter RM, Belperio JA, Arenberg DA, Smith MI, Burdick MD, Keane MP. CXC chemokines in angiogenesis. In: Universes in Delicate Balance: Chemokines and the Nervous System. Ransohoff RM, Suzuki K, Proudfoot AEI, Hickey WF (Eds). Elsevier Science BV, Amsterdam, The Netherlands, 129 (2002).
   Google Scholar
• Belperio JA, Burdick MD, Keane MP et al. The role of the CC chemokine, RANTES, in acute lung allograft rejection. J. Immunol.165, 461–472 (2002).
   Web of Science ®Google Scholar
• Johrer K, Zelle-Rieser C, Perathoner A et al. Up-regulation of functional chemokine receptor CCR3 in human renal cell carcinoma. Clin. Cancer Res.11, 2459–2465 (2005).
   PubMed Web of Science ®Google Scholar
• Suyama T, Furuya M, Nishiyama M et al. Up-regulation of the interferon γ (IFN-γ)-inducible chemokines IFN-inducible T-cell α chemoattractant and monokine induced by IFN-γ and of their receptor CXC receptor 3 in human renal cell carcinoma. Cancer103, 258–267 (2005).
   PubMed Web of Science ®Google Scholar
• Kondo T, Nakazawa H, Ito F et al. Favorable prognosis of renal cell carcinoma with increased expression of chemokines associated with a Th1-type immune response. Cancer Sci.97, 780–786 (2006).
   PubMed Web of Science ®Google Scholar
• Klatte T, Seligson DB, Leppert JT et al. The chemokine receptor CXCR3 is an independent prognostic factor in patients with localized clear cell renal cell carcinoma. J. Urol.179, 61–66 (2008).
   PubMed Web of Science ®Google Scholar
• Tannenbaum CS, Tubbs R, Armstrong D, Finke JH, Bukowski RM, Hamilton TA. The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumor. J. Immunol.161, 927–932 (1998).
   PubMed Web of Science ®Google Scholar
• Ravaud A, Trufflandier N, Ferriere JM et al. Subcutaneous interleukin-2, interferon α-2b and 5-fluorouracil in metastatic renal cell carcinoma as second-line treatment after failure of previous immunotherapy: a Phase II trial. Br. J. Cancer89, 2213–2218 (2003).
   PubMed Web of Science ®Google Scholar
• Negrier S, Escudier B, Lasset C et al. Recombinant human interleukin-2, recombinant human interferon α-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d’Immunotherapie. N. Engl. J. Med.338, 1272–1278 (1998).
   PubMed Web of Science ®Google Scholar
• McDermott DF, Regan MM, Clark JI et al. Randomized Phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J. Clin. Oncol.23, 133–141 (2005).
   PubMed Web of Science ®Google Scholar
• Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J. Clin. Oncol.13, 688–696 (1995).
   PubMed Web of Science ®Google Scholar
• Yang JC, Sherry RM, Steinberg SM et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J. Clin. Oncol.21, 3127–3132 (2003).
   PubMed Web of Science ®Google Scholar
• Reckamp KL, Figlin RA, Moldawer N et al. Expression of CXCR3 on mononuclear cells and CXCR3 ligands in patients with metastatic renal cell carcinoma in response to systemic IL-2 therapy. J. Immunother.30(4), 417–24 (2007).
   PubMed Web of Science ®Google Scholar
• Strieter RM. Chemokines: not just leukocyte chemoattractants in the promotion of cancer. Nat. Immunol.2, 285–286 (2001).
   PubMed Web of Science ®Google Scholar
• Pan J, Burdick MD, Belperio JA et al. CXCR3/CXCR3 ligand biological axis impairs RENCA tumor growth by a mechanism of immunoangiostasis. J. Immunol.176, 1456–1464 (2006).
   PubMed Web of Science ®Google Scholar
• Balkwill F. The significance of cancer cell expression of the chemokine receptor CXCR4. Semin. Cancer Biol.4, 171–179 (2004).
   Google Scholar
• Kucia M, Jankowski K, Reca R et al. CXCR4-SDF-1 signalling, locomotion, chemotaxis and adhesion. J. Mol. Histol.35, 233–245 (2004).
   PubMed Web of Science ®Google Scholar
• Phillips RJ, Burdick MD, Lutz M, Belperio JA, Keane MP, Strieter RM. The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases. Am. J. Respir. Crit. Care Med.167, 1676–1686 (2003).
   PubMed Web of Science ®Google Scholar
• Zlotnik A. Chemokines in neoplastic progression. Semin. Cancer Biol.14, 181–185 (2004).
   PubMed Web of Science ®Google Scholar
• Balkwill F. Chemokine biology in cancer. Semin. Immunol.15, 49–55 (2003).
   PubMed Web of Science ®Google Scholar
• Murphy PM. Chemokines and the molecular basis of cancer metastasis. N. Engl. J. Med.345, 833–835 (2001).
   PubMed Web of Science ®Google Scholar
• Horuk R. Chemokine receptors. Cytokine Growth Factor Rev.12, 313–335 (2001).
   PubMed Web of Science ®Google Scholar
• Burger JA, Kipps TJ. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood107, 1761–1767 (2006).
   PubMed Web of Science ®Google Scholar
• Pan J, Mestas J, Burdick MD et al. Stromal derived factor-1 (SDF-1/CXCL12) and CXCR4 in renal cell carcinoma metastasis. Mol. Cancer5, 56 (2006).
   PubMed Web of Science ®Google Scholar
• Hu J, Deng X, Bian X et al. The expression of functional chemokine receptor CXCR4 is associated with the metastatic potential of human nasopharyngeal carcinoma. Clin. Cancer Res.11, 4658–4665 (2005).
   PubMed Web of Science ®Google Scholar
• Schimanski CC, Schwald S, Simiantonaki N et al. Effect of chemokine receptors CXCR4 and CCR7 on the metastatic behavior of human colorectal cancer. Clin. Cancer Res.11, 1743–1750 (2005).
   PubMed Web of Science ®Google Scholar
• Cabioglu N, Yazici MS, Arun B et al. CCR7 and CXCR4 as novel biomarkers predicting axillary lymph node metastasis in T1 breast cancer. Clin. Cancer Res.11, 5686–5693 (2005).
   PubMed Web of Science ®Google Scholar
• Yasumoto K, Koizumi K, Kawashima A et al. Role of the CXCL12/CXCR4 axis in peritoneal carcinomatosis of gastric cancer. Cancer Res.66, 2181–2187 (2006).
   PubMed Web of Science ®Google Scholar
• Schrader AJ, Lechner O, Templin M et al. CXCR4/CXCL12 expression and signalling in kidney cancer. Br. J. Cancer86, 1250–1256 (2002).
   PubMed Web of Science ®Google Scholar
• Yao M, Yoshida M, Kishida T et al. VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. J. Natl. Cancer Inst.94, 1569–1575 (2002).
   PubMed Web of Science ®Google Scholar
• Banks RE, Tirukonda P, Taylor C et al. Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer. Cancer Res.66, 2000–2011 (2006).
   PubMed Web of Science ®Google Scholar
• Smits KM, Schouten LJ, van Dijk BA et al. Genetic and epigenetic alterations in the von Hippel-Lindau gene: the influence on renal cancer prognosis. Clin. Cancer Res.14, 782–787 (2008).
   PubMed Web of Science ®Google Scholar
• Klatte T, Seligson DB, Riggs SB et al. Hypoxia-inducible factor 1 α in clear cell renal cell carcinoma. Clin. Cancer Res.13, 7388–7393 (2007).
   PubMed Web of Science ®Google Scholar
• Schioppa T, Uranchimeg B, Saccani A et al. Regulation of the chemokine receptor CXCR4 by hypoxia chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. J. Exp. Med.198, 1391–1402 (2003).
   PubMed Web of Science ®Google Scholar
• Staller P, Sulitkova J, Lisztwan J, Moch H, Oakeley EJ, Krek W. Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature425, 307–311 (2003).
   PubMed Web of Science ®Google Scholar
• Pantuck AJ, Zeng G, Belldegrun AS, Figlin RA. Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway. Clin. Cancer Res.9, 4641–4652 (2003).
   PubMed Web of Science ®Google Scholar
• Ceradini DJ, Kulkarni AR, Callaghan MJ et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat. Med.10, 858–864 (2004).
   PubMed Web of Science ®Google Scholar
• Schioppa T, Uranchimeg B, Saccani A et al. Regulation of the chemokine receptor CXCR4 by hypoxia. J. Exp. Med.198, 1391–1402 (2003).
   PubMed Web of Science ®Google Scholar
• Zagzag D, Krishnamachary B, Yee H et al. Stromal cell-derived factor-1α and CXCR4 expression in hemangioblastoma and clear cell-renal cell carcinoma: von Hippel-Lindau loss-of-function induces expression of a ligand and its receptor. Cancer Res.65, 6178–6188 (2005).
   PubMed Web of Science ®Google Scholar
• Caruz A, Samsom M, Alonso JM et al. Genomic organization and promoter characterization of human CXCR4 gene. FEBS Lett.426, 271–278 (1998).
   PubMed Web of Science ®Google Scholar
• Phillips RJ, Mestas J, Gharaee-Kermani M et al. EGF and hypoxia-induced expression of CXCR4 on non-small cell lung cancer cells is regulated by the phosphatidylinositol 3-kinase/ PTEN/AKT/mammalian target of rapamycin signaling pathway and activation of hypoxia inducible factor-1α. J. Biol. Chem.280, 22473–22481 (2005).
   PubMed Web of Science ®Google Scholar
• Kukreja P, Abdel-Mageed AB, Mondal D, Liu K, Agrawal KC. Up-regulation of CXCR4 expression in PC-3 cells by stromal-derived factor-1α (CXCL12) increases endothelial adhesion and transendothelial migration: role of MEK/ERK signaling pathway-dependent NF-κB activation. Cancer Res.65, 9891–9898 (2005).
   PubMed Web of Science ®Google Scholar